<DOC>
	<DOCNO>NCT00739024</DOCNO>
	<brief_summary>The purpose study see ramelteon reduce number migraine headache 12 week period . The safety tolerability ramelteon also evaluate . Ramelteon approve U.S. Food Drug Administration ( FDA ) insomnia ( trouble sleep ) ; however ; ramelteon approve prevention migraine .</brief_summary>
	<brief_title>A Study Melatonin Receptor Agonist Prevent Migraine</brief_title>
	<detailed_description>Sleep play important role migraine . Younger migraine sufferer usually report relief migraine sleep . In old migraine sufferer migraine sometimes trigger sleep change . Occurrence migraine early morning common . Therefore individual regulation sleep may improve frequency migraine . Recent PET study do migraine demonstrate activation hypothalamus migraine . In light new data know action ramelteon melatonin receptor may theoretically provide insight possible mechanism action migraine .</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Migraine without Aura</mesh_term>
	<mesh_term>Migraine Aura</mesh_term>
	<criteria>Male female , age 18 65 year , inclusive . An established history migraine , without aura probable migraine , conform revise IHS criterion ( 2004 ) least 1 year screening , sufficient establish diagnosis . To randomize , prospective 4week baseline period ( approximately 28 day Visit 2 ) , subject must 4 migraine/probable migraine attack per month ( use 24hour rule ) . Must le 50 year age time initial migraine onset . Must clinically significant relevant abnormality physical neurologic examination Must complete washout prophylactic medication migraine start 4week prospective baseline period ( ie , 28 day Visit 2 , randomization occurs ) . Female subject must least 1 follow : postmenopausal , surgically incapable child , practice highly effective method birth control Most frequent type headache meet revise IHS diagnostic criterion migraine aura without aura probable migraine . Pregnant lactate woman , sexually active woman childbearing potential use appropriate method contraception . Failed adequate trial prophylactic agent demonstrate possible efficacy prophylaxis migraine . These agent include betablockers , tricyclic antidepressant , valproate , topiramate , methysergide . Unable complete diary timely accurate manner migraine headache attack , either independently assistance . Overuse analgesic specific agent abortive treatment migraine attack , make investigator suspect medication overuse headache . Receiving nonpharmacological prophylactic treatment acupuncture , chiropractic , massage , start less 1 month screen visit ( Day 28 ) . These therapy may continue started time . Currently abuse alcohol drug . Have central nervous system neoplasm infection , demyelinate disease , degenerative progressive central nervous system disease , active epilepsy . History serious systemic disease , include hepatic insufficiency , renal insufficiency , malignant neoplasm , disorder prognosis survival le 3 month , disorder judgment investigator place subject excessive risk participation control trial . Have significant psychiatric disorder , acute psychosis , schizophrenia , severe bipolar disorder , severe unipolar mood disorder , sufficient severity preclude safe effective participation subject study . Require continue use protocoldefined prohibited medication study Have recent remote history suicide attempt ideation Known strongly suspect noncompliant administer daily medication . Received experimental drug use experimental device within 30 day Screening Visit . Employees investigator study center , direct involvement propose study study direction investigator study center , well family member employee investigator Any reason investigator , upon evaluation , feel subject 's best interest continue study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Migraine</keyword>
	<keyword>Headache</keyword>
</DOC>